Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy...

Area of Science:

• Oncology
• Immunology
• Radiotherapy

Background:

• Radiotherapy (RT) is a cornerstone cancer treatment, historically focused on direct tumor cell killing.
• Emerging evidence highlights RT's immunomodulatory effects on the tumor microenvironment.
• Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, but durable responses are limited.

Purpose of the Study:

• To explore the potential of combining RT with immuno-oncology (IO) agents.
• To investigate how RT influences the tumor microenvironment, particularly immunosuppressive myeloid cells.
• To identify strategies for optimizing RT and IO combinations for improved cancer treatment outcomes.

Main Methods:

• Review of current literature on RT, IO, and the tumor microenvironment.
• Analysis of the interplay between RT, immune cells, and tumor progression.
• Discussion of potential therapeutic manipulations of immunosuppressive myeloid populations.

Main Results:

• RT can stimulate anti-tumor immunity, making it a promising partner for ICIs.
• RT may exacerbate immunosuppression in certain tumor microenvironments, posing a clinical challenge.
• Understanding the role of myeloid-derived cells is crucial for successful RT-IO combinations.

Conclusions:

• Combining RT with IO agents holds significant promise for enhancing anti-tumor immunity and patient outcomes.
• Further research is needed to elucidate the complex interactions between RT, immunosuppressive cells, and IO therapies.
• Optimizing RT parameters (dose, fractionation, volume) and scheduling with IO agents is essential for maximizing therapeutic efficacy.